Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 16;22(1):284.
doi: 10.1186/s12967-024-05058-1.

Predictive biomarkers for anti-TNF alpha therapy in IBD patients

Manoj Kumar  1 , Selvasankar Murugesan  1 , Nazira Ibrahim  2 , Mamoun Elawad  2 , Souhaila Al Khodor  3
Affiliations
Review

Predictive biomarkers for anti-TNF alpha therapy in IBD patients

Manoj Kumar et al. J Transl Med. .

Abstract

Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition characterized by severe gut inflammation, commonly presenting as Crohn's disease, ulcerative colitis or categorized as IBD- unclassified. While various treatments have demonstrated efficacy in adult IBD patients, the advent of anti-TNF therapies has significantly revolutionized treatment outcomes and clinical management. These therapies have played a pivotal role in achieving clinical and endoscopic remission, promoting mucosal healing, averting disease progression, and diminishing the necessity for surgery. Nevertheless, not all patients exhibit positive responses to these therapies, and some may experience a loss of responsiveness over time. This review aims to present a comprehensive examination of predictive biomarkers for monitoring the therapeutic response to anti-TNF therapy in IBD patients. It will explore their limitations and clinical utilities, paving the way for a more personalized and effective therapeutic approach.

Keywords: Adalimumab; Anti-TNF; Crohn’s disease; Inflammatory Bowel disease; Infliximab; Markers; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Molecular resistance mechanisms to anti-TNF therapy in IBD Patients. MOA mechanism of action
See this image and copyright information in PMC

References

    1. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217. doi: 10.1038/nrgastro.2015.34. - DOI - PubMed
    1. Kumar M, Garand M, Al KS. Integrating omics for a better understanding of Inflammatory Bowel disease: a step towards personalized medicine. J Transl Med. 2019;17:419. doi: 10.1186/s12967-019-02174-1. - DOI - PMC - PubMed
    1. Everhov AH, Sachs MC, Malmborg P, Nordenvall C, Myrelid P, Khalili H, Elmberg M, Ekbom A, Askling J, Jakobsson G, Halfvarson J, Ludvigsson JF, Olen O. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastroenterol. 2019;54:55–63. doi: 10.1080/00365521.2018.1564361. - DOI - PubMed
    1. Perler BK, Ungaro R, Baird G, Mallette M, Bright R, Shah S, Shapiro J, Sands BE. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. BMC Gastroenterol. 2019;19:47. doi: 10.1186/s12876-019-0963-7. - DOI - PMC - PubMed
    1. Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol. 2016;22:1017–1033. doi: 10.3748/wjg.v22.i3.1017. - DOI - PMC - PubMed

Publication types

MeSH terms